Effects / Benefits

Enzogenol®  pure pine bark extract supports healthy brain functioning including concentration ability alertness, executive functioning and shor term memory. Extra-DHA Omega-3 provides the esssential fatty acids the brain requires to maintain its structural and functional integrity. Increasing flavonoid DHA intake with Enzogenol® may reduce cognitive decline with age. 

Clinical Research

Clinical Research: In a RCT of 50-65 year-old men, overweight with a sedentary occupation, taking 960mg Enzogenol per day for 5 weeks led to significant improvements on computer-based cognitive tests, compared to the placebo controls. Furthermore, this study identified significant changes in brain activities in the men taking Enzogenol that were indicative of improvements in concentration and correlated strongly with accurate decision making on the cognitive tests1,2. Based on the average decline in brain performance with age seen in the normal population, the brain science researchers concluded that Enzogenol led to a recovery in functional brain age of between 7 to 12 years.
Epidemiological research on flavonoids and brain function has shown that cognitive decline with age is more severe in people that consume less flavonoids3. Taking just one capsule per day of ENZO Brain Recovery will increase flavonoid intake substantially, and may help to reduce cognitive decline with age. 

A recent clinical study in mild to moderate Alzheimer patients found that taking the Extra-DHA Omega-3 (equiv. 10 caps/day of ENZO Brain Recovery) for six months slowed down the decline in people with very mild cognitive dysfunction. One group took the ω-3 for 12 months, and one group first took placebo for 6 months and was then given ω-3. Shown to the left are the mean MMSE scores over the 12 months4. 

Taking the Extra-DHA Omega-3 also led to a significant increase of DHA and EPA in the blood serum which has many additional health benefits for heart, eyes, blood circulation, cholesterol levels and the body’s inflammatory responses4. 

1) Pipingas & Silberstein Journal of Clinical EEG & Neuroscience 16th Annual Conference of the Australasian Society for Psychophysiology, Dec 9-11, 2006.
2) Pipingas et al. 2008. Phytotherapy Research 22, p1168 3) Letenneur L, et al, 2007, American Journal of Epidemiology 165: 1364. 4) Freund-Levi, Y. et al. 2006.
Archives of Neurology, Vol 63, p1402.